6-phosphofructose-2-kinase (PFKFB3) serves as a rate limiting enzyme for glycolysis, the use of PFKFB3 inhibitors restrained the expression of SOX2, downregulated YAP/TAZ signaling, and enhanced the chemotherapy response of CSCs and EMT in SCLC [71]. The gene discussed is SOX2; the disease is small cell lung carcinoma.